KFAS
BCRX icon

Keating Financial Advisory Services’s BioCryst Pharmaceuticals BCRX Stock Holding History

Keating Financial Advisory Services’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$480 Sell
48
-19
-28% -$172 ﹤0.01% 2344
2026
Q1 		$638 Buy
+67
New +$520 ﹤0.01% 2209

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Keating Financial Advisory Services's BCRX Position: Q2 2026 in Review

Keating Financial Advisory Services reduced its BioCryst Pharmaceuticals (BCRX) stake by 28% in Q2 2026, selling an estimated $172 and leaving 48 shares worth $480. The position accounts for ﹤0.01% of the portfolio, ranked #2344.

Keating Financial Advisory Services first reported a position in BCRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $638 in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Keating Financial Advisory Services held 48 shares of BioCryst Pharmaceuticals worth $480 as of Q2 2026.
  • Keating Financial Advisory Services sold 19 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $172.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2344 holding.
  • Keating Financial Advisory Services first reported a position in BioCryst Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Keating Financial Advisory Services's BioCryst Pharmaceuticals position peaked at $638 in Q1 2026.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.